We have enhanced our existing forensic services with new cutting-edge digital forensics software package, and we are working on adding more certified forensic experts to our staff.
Accelerate indication identification and early licensing with FRONTEO’s unique technologies that systematically discovers unreported relationships between diseases and molecules from existing literature information.
FRONTEO, Inc. (Head Office: Minato-ku, Tokyo; President and CEO: Masahiro Morimoto; hereafter "FRONTEO") is pleased to announce that an agreement has been reached to provide Daiichi Sankyo Co., Ltd. (Head Office: Chuo-ku, Tokyo; President and COO: Hiroyuki Okuzawa; hereafter "Daiichi Sankyo") with analysis services using Drug Discovery AI Factory (hereafter "DDAIF")* to analyze text information from toxicity study databases and reports.
Expanded the functions of the AI review tool “KIBIT Automator” which is a key to FRONTEO’s portfolio transformation, enabling one-stop handling of eDiscovery process from pre-processing to document review.
NEW YORK, October 5, 2023 – FRONTEO (TSE: 2158) is pleased to announce that Shiho Tanaka, Global Sales Executive, LegalTech AI Division, FRONTEO, Inc and Senior Vice President, Data Science & Technology Department, FRONTEO USA, will be speaking at the 5th White Collar Crime Workshop 2023, organized by Daisuke Fukamizu of Nagashima Ohno & Tsunematsu, LLP.
FRONTEO, Inc. (Headquarters: Minato-ku, Tokyo; President & CEO: Masahiro Morimoto) is hosting a free seminar “Recent Developments in AI and Competition Law – a Global Perspective” in collaboration with White & Case LLP on March 19th.